PL2091940T3 - Związki oparte na 4-fenylo-6-(2,2,2-trifluoro-1-fenyloetoksy)pirymidynie i ich zastosowania - Google Patents
Związki oparte na 4-fenylo-6-(2,2,2-trifluoro-1-fenyloetoksy)pirymidynie i ich zastosowaniaInfo
- Publication number
- PL2091940T3 PL2091940T3 PL07865487T PL07865487T PL2091940T3 PL 2091940 T3 PL2091940 T3 PL 2091940T3 PL 07865487 T PL07865487 T PL 07865487T PL 07865487 T PL07865487 T PL 07865487T PL 2091940 T3 PL2091940 T3 PL 2091940T3
- Authority
- PL
- Poland
- Prior art keywords
- phenylethoxy
- trifluoro
- pyrimidine
- phenyl
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87459606P | 2006-12-12 | 2006-12-12 | |
EP07865487.8A EP2091940B3 (en) | 2006-12-12 | 2007-12-11 | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use |
PCT/US2007/087068 WO2008073933A2 (en) | 2006-12-12 | 2007-12-11 | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use |
Publications (2)
Publication Number | Publication Date |
---|---|
PL2091940T3 true PL2091940T3 (pl) | 2016-06-30 |
PL2091940T6 PL2091940T6 (pl) | 2018-05-30 |
Family
ID=39432875
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL07865487T PL2091940T6 (pl) | 2006-12-12 | 2007-12-11 | Związki oparte na 4-fenylo-6-(2,2,2-trifluoro-1-fenyloetoksy)pirymidynie i ich zastosowania |
PL16206493T PL3176159T3 (pl) | 2006-12-12 | 2007-12-11 | Związki oparte na 4-fenylo-6-(2,2,2-trifluoro-1-fenyloetoksy)pirymidynie i ich zastosowanie |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL16206493T PL3176159T3 (pl) | 2006-12-12 | 2007-12-11 | Związki oparte na 4-fenylo-6-(2,2,2-trifluoro-1-fenyloetoksy)pirymidynie i ich zastosowanie |
Country Status (25)
Country | Link |
---|---|
US (4) | US7553840B2 (pl) |
EP (4) | EP2091940B3 (pl) |
JP (1) | JP5361734B2 (pl) |
KR (1) | KR101464391B1 (pl) |
AR (1) | AR064279A1 (pl) |
AU (1) | AU2007333120B2 (pl) |
BR (1) | BRPI0720270B8 (pl) |
CA (1) | CA2672233C (pl) |
CO (1) | CO6220855A2 (pl) |
DK (2) | DK3176159T3 (pl) |
EA (1) | EA018150B1 (pl) |
EC (1) | ECSP099413A (pl) |
ES (3) | ES2562775T7 (pl) |
HU (3) | HUE027896T2 (pl) |
IL (2) | IL198806A (pl) |
MX (1) | MX2009006195A (pl) |
NL (1) | NL300929I2 (pl) |
NO (2) | NO345062B1 (pl) |
NZ (1) | NZ577004A (pl) |
PL (2) | PL2091940T6 (pl) |
PT (2) | PT2091940E (pl) |
TW (1) | TWI412365B (pl) |
UA (1) | UA99270C2 (pl) |
WO (1) | WO2008073933A2 (pl) |
ZA (1) | ZA200903367B (pl) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7855291B2 (en) * | 2005-12-29 | 2010-12-21 | Lexicon Pharmaceuticals, Inc. | Process for the preparation of substituted phenylalanines |
US7897763B2 (en) * | 2005-12-29 | 2011-03-01 | Lexicon Pharmaceuticals, Inc. | Process for the preparation of substituted phenylalanines |
UA96936C2 (uk) * | 2005-12-29 | 2011-12-26 | Лексикон Фармасьютикалз, Инк. | Поліциклічні похідні амінокислот і їх застосування |
UA99270C2 (en) * | 2006-12-12 | 2012-08-10 | Лексикон Фармасьютикалз, Инк. | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use |
MX2009013990A (es) * | 2007-06-26 | 2010-03-30 | Lexicon Pharmaceuticals Inc | Metodos para tratar enfermedades y trastornos mediados por serotonina. |
MX2009013982A (es) * | 2007-06-26 | 2010-04-09 | Lexicon Pharmaceuticals Inc | Composiciones que comprenden inhibidores de triptofano hidroxilasa. |
EP2170397A1 (en) * | 2007-07-11 | 2010-04-07 | Lexicon Pharmaceuticals, Inc. | Methods and compositions for treating pulmonary hypertension and related diseases and disorders |
AU2008279426A1 (en) * | 2007-07-26 | 2009-01-29 | Lexicon Pharmaceuticals, Inc. | Methods of affecting gastrointestinal transit and gastric emptying, and compounds useful therein |
EP3318260B1 (en) * | 2007-08-24 | 2020-09-23 | Lexicon Pharmaceuticals, Inc. | Methods of preparing 4-phenyl-6-(2,2,2- trifluoro-1-phenylethoxy) pyrimidine-based compounds |
TWI439457B (zh) | 2007-09-28 | 2014-06-01 | Lexicon Pharmaceuticals Inc | (s)-2-胺基-3-(4-(2-胺基-6-((r)-1-(4-氯-2-(3-甲基-1h-吡唑-1-基)苯基)-2,2,2-三氟乙氧)-嘧啶-4-基)苯基)丙酸乙酯之固體形式與其使用方法 |
TW200932729A (en) * | 2007-10-08 | 2009-08-01 | Lexicon Pharmaceuticals Inc | Solid forms of (S)-2-amino-3-(4-(2-amino-6-((R)-2,2,2-trifluoro-1-(3'-methoxybiphenyl-4-yl)ethoxy)pyrimidin-4-yl)phenyl)propanoic acid and methods of their use |
BRPI0908719A2 (pt) * | 2008-03-31 | 2015-08-18 | Univ Columbia | Metodos de diagnóstico, prevenção e tratamento de doenças de massa óssea |
AU2008363274A1 (en) * | 2008-10-24 | 2010-04-29 | Lexicon Pharmaceuticals, Inc. | Process for the preparation of substituted phenylalanines |
US8614222B2 (en) | 2008-11-13 | 2013-12-24 | The Trustees Of Columbia University In The City Of New York | Methods of preventing and treating low bone mass diseases |
WO2010065333A1 (en) * | 2008-12-01 | 2010-06-10 | Lexicon Pharmaceuticals, Inc. | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds for the treatment of osteoporosis |
US8815883B2 (en) | 2009-11-02 | 2014-08-26 | The Trustees Of Columbia Unviersity In The City Of New York | Compounds and methods for inhibiting serotonin synthesis |
US20120316171A1 (en) * | 2009-11-05 | 2012-12-13 | Tamas Oravecz | Tryptophan Hydroxylase Inhibitors for the Treatment of Cancer |
JP2013511531A (ja) | 2009-11-19 | 2013-04-04 | レクシコン ファーマシューティカルズ インコーポレイテッド | 置換フェニルアラニンを調製するプロセス |
US20120077831A1 (en) * | 2009-11-23 | 2012-03-29 | Philip Manton Brown | Methods and assays for the treatment of irritable bowel syndrome |
CN102711757A (zh) * | 2009-11-23 | 2012-10-03 | 莱西肯医药有限公司 | 用于治疗肠易激综合征的方法和分析法 |
US20130137635A1 (en) * | 2010-02-10 | 2013-05-30 | Lexicon Pharmaceuticals, Inc. | Tryptophan hydroxylase inhibitors for the treatment of metastatic bone disease |
WO2012009372A2 (en) * | 2010-07-12 | 2012-01-19 | Colorado State University Research Foundation | Triazolium carbene catalysts and processes for asymmetric carbon-carbon bond formation |
US20130338176A1 (en) * | 2010-10-29 | 2013-12-19 | The Trustees Of Columbia University In The City Of New York | Methods of preventing and treating hyperlipidemia or atherosclerosis |
TW201245183A (en) * | 2010-11-05 | 2012-11-16 | Lexicon Pharmaceuticals Inc | Solid forms of (S)-2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoic acid |
JP2012156602A (ja) * | 2011-01-21 | 2012-08-16 | Ricoh Co Ltd | 情報処理装置、通信制御方法、及び通信制御システム |
KR101682417B1 (ko) * | 2011-02-25 | 2016-12-06 | 주식회사유한양행 | 다이아미노피리미딘 유도체 및 그의 제조방법 |
UA114412C2 (uk) * | 2011-10-17 | 2017-06-12 | Лексікон Фармасьютікалз, Інк. | Тверда дозована форма гіпурату (s)-2-аміно-3-(4-(2-аміно-6-((r)-1-(4-хлор-2-(3-метил-1h-піразол-1-іл)феніл)-2,2,2-трифторетокси)піримідин-4-іл)феніл)пропаноату |
WO2013148978A1 (en) | 2012-03-30 | 2013-10-03 | Lexicon Pharmaceuticals, Inc. | Methods and compositions for the treatment of necrotizing enterocolitis |
WO2014195847A2 (en) | 2013-06-03 | 2014-12-11 | Actelion Pharmaceuticals Ltd | Novel use of stable isotope labeled l-tryptophan |
UA119247C2 (uk) | 2013-09-06 | 2019-05-27 | РОЙВЕНТ САЙЕНСИЗ ҐмбГ | Спіроциклічні сполуки як інгібітори триптофангідроксилази |
US10189839B2 (en) | 2013-11-19 | 2019-01-29 | Actelion Pharmaceuticals Ltd | Tricyclic imidazole compounds as inhibitors of tryptophan hydroxylase |
AR098436A1 (es) * | 2013-11-19 | 2016-05-26 | Actelion Pharmaceuticals Ltd | Compuestos tricíclicos de piperidina |
US9611201B2 (en) | 2015-03-05 | 2017-04-04 | Karos Pharmaceuticals, Inc. | Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone |
CA2980100A1 (en) * | 2015-05-04 | 2016-11-10 | Actelion Pharmaceuticals Ltd | Tricyclic piperidine compounds |
TW201818964A (zh) | 2016-09-30 | 2018-06-01 | 瑞士商諾伊曼特醫療公司 | 使用色胺酸羥化酶抑制劑之方法 |
PL3762368T3 (pl) | 2018-03-08 | 2022-06-06 | Incyte Corporation | ZWIĄZKI AMINOPIRAZYNODIOLOWE JAKO INHIBITORY PI3K-γ |
WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
CN109020958A (zh) * | 2018-08-28 | 2018-12-18 | 湖南华腾制药有限公司 | 一种氘代色氨酸羟化酶抑制剂 |
CN109180650A (zh) * | 2018-08-28 | 2019-01-11 | 湖南华腾制药有限公司 | 一种氘代色氨酸羟化酶抑制剂的晶型 |
WO2023192003A1 (en) | 2022-04-01 | 2023-10-05 | Tersera Therapeutics Llc | Methods of reducing the likelihood of carcinoid heart disease in patients with neuroendocrine tumors |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
AU660852B2 (en) | 1992-11-25 | 1995-07-06 | Elan Pharma International Limited | Method of grinding pharmaceutical substances |
US5718388A (en) | 1994-05-25 | 1998-02-17 | Eastman Kodak | Continuous method of grinding pharmaceutical substances |
TW384224B (en) | 1994-05-25 | 2000-03-11 | Nano Sys Llc | Method of preparing submicron particles of a therapeutic or diagnostic agent |
US5662883A (en) | 1995-01-10 | 1997-09-02 | Nanosystems L.L.C. | Microprecipitation of micro-nanoparticulate pharmaceutical agents |
US5665331A (en) | 1995-01-10 | 1997-09-09 | Nanosystems L.L.C. | Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers |
US5534270A (en) | 1995-02-09 | 1996-07-09 | Nanosystems Llc | Method of preparing stable drug nanoparticles |
US5510118A (en) | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
US5543133A (en) | 1995-02-14 | 1996-08-06 | Nanosystems L.L.C. | Process of preparing x-ray contrast compositions containing nanoparticles |
US5718919A (en) | 1995-02-24 | 1998-02-17 | Nanosystems L.L.C. | Nanoparticles containing the R(-)enantiomer of ibuprofen |
US5834025A (en) | 1995-09-29 | 1998-11-10 | Nanosystems L.L.C. | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
US5958957A (en) | 1996-04-19 | 1999-09-28 | Novo Nordisk A/S | Modulators of molecules with phosphotyrosine recognition units |
EP1185371B2 (en) | 1999-06-01 | 2008-11-12 | Elan Pharma International Limited | Small-scale mill and method thereof |
WO2002000651A2 (en) | 2000-06-27 | 2002-01-03 | Bristol-Myers Squibb Pharma Company | Factor xa inhibitors |
DE10112768A1 (de) | 2001-03-16 | 2002-09-19 | Merck Patent Gmbh | Phenylderivate 3 |
PT1392441E (pt) | 2001-06-05 | 2008-09-30 | Elan Pharma Int Ltd | Sistema e método para trituração de materiais |
US6976647B2 (en) | 2001-06-05 | 2005-12-20 | Elan Pharma International, Limited | System and method for milling materials |
US7181071B2 (en) * | 2001-11-27 | 2007-02-20 | Samsung Electronics Co., Ltd. | Method and apparatus for encoding and decoding key value data of orientation interpolator node |
SI1553927T1 (sl) | 2002-09-11 | 2010-12-31 | Elan Pharma Int Ltd | Z gelom stabilizirani nanodeläśni sestavki uäśinkovine |
US20070105959A1 (en) | 2003-03-11 | 2007-05-10 | Shinya Kusuda | Cynnamyl alcohol derivative compounds and drugs containing the compounds as active ingredient |
US20050234066A1 (en) | 2004-04-15 | 2005-10-20 | Agouron Pharmaceuticals, Inc. | Alpha substituted carboxylic acids |
US20050187266A1 (en) | 2003-04-15 | 2005-08-25 | Pfizer Inc | Alpha substituted carboxylic acids |
US7244739B2 (en) | 2003-05-14 | 2007-07-17 | Torreypines Therapeutics, Inc. | Compounds and uses thereof in modulating amyloid beta |
US20050042177A1 (en) | 2003-07-23 | 2005-02-24 | Elan Pharma International Ltd. | Novel compositions of sildenafil free base |
US7377637B2 (en) * | 2005-10-11 | 2008-05-27 | Synergeyes, Inc. | Hybrid contact lens system and method of fitting |
UA96936C2 (uk) * | 2005-12-29 | 2011-12-26 | Лексикон Фармасьютикалз, Инк. | Поліциклічні похідні амінокислот і їх застосування |
UA99270C2 (en) * | 2006-12-12 | 2012-08-10 | Лексикон Фармасьютикалз, Инк. | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use |
EP3318260B1 (en) * | 2007-08-24 | 2020-09-23 | Lexicon Pharmaceuticals, Inc. | Methods of preparing 4-phenyl-6-(2,2,2- trifluoro-1-phenylethoxy) pyrimidine-based compounds |
TWI439457B (zh) * | 2007-09-28 | 2014-06-01 | Lexicon Pharmaceuticals Inc | (s)-2-胺基-3-(4-(2-胺基-6-((r)-1-(4-氯-2-(3-甲基-1h-吡唑-1-基)苯基)-2,2,2-三氟乙氧)-嘧啶-4-基)苯基)丙酸乙酯之固體形式與其使用方法 |
-
2007
- 2007-11-12 UA UAA200907262A patent/UA99270C2/uk unknown
- 2007-12-10 TW TW096147104A patent/TWI412365B/zh active
- 2007-12-11 BR BRPI0720270A patent/BRPI0720270B8/pt active IP Right Grant
- 2007-12-11 PT PT78654878T patent/PT2091940E/pt unknown
- 2007-12-11 EP EP07865487.8A patent/EP2091940B3/en active Active
- 2007-12-11 JP JP2009541514A patent/JP5361734B2/ja active Active
- 2007-12-11 PT PT162064935T patent/PT3176159T/pt unknown
- 2007-12-11 HU HUE07865487A patent/HUE027896T2/en unknown
- 2007-12-11 CA CA2672233A patent/CA2672233C/en not_active Expired - Fee Related
- 2007-12-11 ZA ZA200903367A patent/ZA200903367B/xx unknown
- 2007-12-11 EA EA200970575A patent/EA018150B1/ru not_active IP Right Cessation
- 2007-12-11 ES ES07865487.8T patent/ES2562775T7/es active Active
- 2007-12-11 PL PL07865487T patent/PL2091940T6/pl unknown
- 2007-12-11 ES ES13153803.5T patent/ES2625083T3/es active Active
- 2007-12-11 NZ NZ577004A patent/NZ577004A/en unknown
- 2007-12-11 WO PCT/US2007/087068 patent/WO2008073933A2/en active Application Filing
- 2007-12-11 AU AU2007333120A patent/AU2007333120B2/en active Active
- 2007-12-11 HU HUE16206493A patent/HUE053098T2/hu unknown
- 2007-12-11 US US11/954,000 patent/US7553840B2/en active Active
- 2007-12-11 EP EP13153803.5A patent/EP2589600B1/en active Active
- 2007-12-11 PL PL16206493T patent/PL3176159T3/pl unknown
- 2007-12-11 AR ARP070105537A patent/AR064279A1/es active IP Right Grant
- 2007-12-11 EP EP16206493.5A patent/EP3176159B1/en active Active
- 2007-12-11 KR KR1020097012100A patent/KR101464391B1/ko active IP Right Grant
- 2007-12-11 ES ES16206493T patent/ES2856871T3/es active Active
- 2007-12-11 DK DK16206493.5T patent/DK3176159T3/da active
- 2007-12-11 DK DK07865487.8T patent/DK2091940T6/en active
- 2007-12-11 MX MX2009006195A patent/MX2009006195A/es active IP Right Grant
- 2007-12-11 EP EP20191197.1A patent/EP3808740A1/en not_active Withdrawn
-
2009
- 2009-05-19 IL IL198806A patent/IL198806A/en active IP Right Grant
- 2009-05-20 US US12/468,974 patent/US7709493B2/en active Active
- 2009-06-12 CO CO09061621A patent/CO6220855A2/es not_active Application Discontinuation
- 2009-06-12 EC EC2009009413A patent/ECSP099413A/es unknown
- 2009-07-10 NO NO20092639A patent/NO345062B1/no active Protection Beyond IP Right Term
-
2010
- 2010-04-05 US US12/754,341 patent/US7968559B2/en active Active
-
2011
- 2011-06-17 US US13/162,989 patent/US8772482B2/en active Active
-
2014
- 2014-10-23 IL IL235288A patent/IL235288A/en active IP Right Grant
-
2018
- 2018-02-14 NL NL300929C patent/NL300929I2/nl unknown
- 2018-02-19 HU HUS1800010C patent/HUS1800010I1/hu unknown
-
2021
- 2021-03-01 NO NO2021010C patent/NO2021010I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS1800010I1 (hu) | 4-Fenil-6-(2,2,2-trifluor-1-feniletoxi)pirimidin-alapú vegyületek és alkalmazási eljárásaik | |
IL244442B (en) | Compounds of converted acylanilides and their use | |
PL1996557T3 (pl) | Związki pirydazynonu i ich wykorzystanie jako herbicydy | |
IL196956A0 (en) | Aza-benzofuranyl compounds and methods of use | |
EP2023718A4 (en) | CREATINLIGATE COMPOUNDS AND APPLICATION METHOD THEREFOR | |
PL2057153T3 (pl) | POCHODNE (3-ARYLO-PIPERAZYN-1-YLOWE) 6,7-DIALKOKSYCHINAZOLINY, 6,7-DIALKOKSYFTALAZYNY i 6,7-DIALKOKSYIZOCHINOLINY | |
IL194028A0 (en) | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | |
IL197060A0 (en) | Aza-benzothiophenyl compounds and methods of use | |
ZA200808431B (en) | Fungicidal compositions and methods of using the same | |
PL378587A1 (pl) | Sposób wytwarzania (S)-(-)-2-amino-6-n-propyloamino-4,5,6,7-tetrahydrobenzotiazolu i/lub jego soli | |
IL185309A0 (en) | Isoqunoline compounds and methods of use thereof | |
EP2046129A4 (en) | HERBICIDE COMPOSITION AND METHOD OF USE | |
HK1137756A1 (en) | Substituted dihydropyrazolones and use thereof as hif-prolyl-4 -hydroxylase inhibitors hif--4- | |
IL194899A0 (en) | Amino-ethyl-amino-aryl (aeaa) compounds and their use | |
EP2046128A4 (en) | HERBICIDAL COMPOSITION AND METHOD FOR THEIR USE | |
HK1135987A1 (en) | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use 4--6-(222--1-) | |
EP2046116A4 (en) | HERBICIDE COMPOSITION AND METHOD OF USE | |
IL226441A0 (en) | Methods for preparing compounds based on 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine | |
ZA200804681B (en) | Inhibitors of C-Met and uses thereof | |
EP2069371A4 (en) | ORGANO ARSENOXIDE COMPOUNDS AND THEIR USE | |
ZA200807796B (en) | Pyridazinone compound and use thereof as herbicides | |
EP2046118A4 (en) | HERBICIDE COMPOSITION AND METHOD OF USE | |
ZA200900896B (en) | Aza-benzofuranyl compounds and methods of use | |
IL192820A0 (en) | Novel compounds and use thereof | |
ZA200901009B (en) | Aza-benzothiophenyl compounds and methods of use |